Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • Hospitals & Diagnostics
    • Fortis extends...

    Fortis extends deadline of binding bids to 3 July

    Written by Ruby Khatun Khatun Published On 2018-06-29T13:44:06+05:30  |  Updated On 29 Jun 2018 1:44 PM IST
    Fortis extends deadline of binding bids to 3 July

    New Delhi: Cash-strapped Fortis Healthcare Ltd, which is currently in the process of finding a new investor, today extended the date for submission of binding bids yet again to 3 July.


    Earlier on 12 June, the company had extended the deadline for submission of binding bids to 28 June after shortlisting four entities—the Munjal-Burman combine, Manipal-TPG consortium, Malaysia’s IHH Healthcare Berhad and Radiant Life Care—as possible suitors for the sale of its business.


    The rest of the details with respect to the timings and submission remain the same, the company said in a BSE filing.


    In May, Fortis Healthcare had initiated a fresh time- bound bidding process for its sale after terminating the offer made by the Munjal-Burman combine. It had set 14 June as the deadline for submitting fresh binding bids.


    As per the criteria set by the company, the buyer have to make a minimum investment of Rs1,500 crore into Fortis Healthcare by way of preferential allotment apart from having a plan for funding the acquisition of RHT Health Trust (RHT) and a plan for providing exit to private equity investors of diagnostic arm SRL.


    Among others, the bids should be unconditional as well as mention the source of funds for the transaction and elaborate on the plans for retention of current management and employees.


    The latest development comes two days after the company announced that it has initiated legal action to recover about Rs500 crore of funds allegedly taken out of the company by its founders Malvinder and Shivinder Singh after an external investigation found “systemic lapses and override of controls” in the loan given.


    At 1.08pm, Fortis shares were down 0.71% to Rs133.80 on BSE.

    Acquisitionbidding processBinding bidsdeadlineextendsFortisFortis HealthcareIHH HealthcareMalvinder SinghManipal/TPG consortiumMunjal-Burman combineRadiant Life CareRHT Health TrustShivinder SinghSRLSRL Diagnostics
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok